Novartis AG (ADR) news

   Watch this stock
Showing stories 1 - 10 of about 139   

Articles published

NVS 89.24 +1.04 (1.18%)
price chart
Novartis Announces Positive Phase-III Results For Secukinumab
Novartis AG (ADR) (NVS) announced today that its experimental drug AIN457 (Secukinumab) met its primary and secondary end points in two late-stage trials called MEASURE 1 and MEASURE-2.
Related articles »  
Stocks Alert: Novartis AG (ADR) (NYSE:NVS), Chimerix Inc (NASDAQ:CMRX ...
Novartis AG (ADR) (NYSE:NVS) said three members of its executive committee will leave the health-care company following the completion of the sales of its animal health, OTC drugs, and vaccine units to Eli Lilly (LLY) and GlaxoSmithKline (GSK).
Related articles »  
FDA Advisory Committee Votes In Favor Of Novartis' IL-17 Inhibitor
Novartis AG (ADR) (NVS) announced yesterday that the Dermatologic and Ophthalmic Drugs Advisory Committee to the FDA has unanimously recommended the use of Novartis' AIN457 in adults who are suffering from moderate-to-severe plaque psoriasis.
Related articles »  
Pharma Stock Updates - Pfizer Inc. (NYSE:PFE), Novartis AG (ADR) (NYSE:NVS ...
Novartis AG (ADR) (NYSE:NVS) said late on Wednesday that its experimental drug secukinumab worker better than a placebo in two pivotal Phase III studies on psoriatic arthritis, a long-lasting condition that causes joint pain and stiffness and which ...
Related articles »  
Eye Catching Stocks: EXCO Resources Inc (NYSE:XCO), Novartis AG (ADR ...
Novartis AG (ADR) (NYSE:NVS) presents data at EADV showing reliable efficiency of AIN457 in clearing skin of psoriasis patients (NVS) : new investigation of AIN457 (secukinumab) Phase III studies explains that treatment with secukinumab 300 mg resulted ...
Related articles »  
Novartis's Signifor Closer To EU Approval
Novartis's Signifor is capable of treating acromegaly in adults, who are unable to go through a surgery as an alternative option, and those on whom first-generation somatostatin analogues (SSAs), including Novartis's Sandostatin LAR, have not worked ...
Novartis Releases Positive Phase 3 Results For Psoriatic Arthritis Drug
Novartis AG (ADR) (NVS) today released top line results for two late-stage pivotal studies, which evaluated its novel drug secukinumab as a treatment for psoriatic arthritis (PsA).
Related articles »  
Pharma Stocks To Look Out For This Week
The US Food and Drug Administration (FDA) is also expected to release briefs for the Advisory Committee's meeting next week to give recommendations on Novartis AG (ADR)'s (NVS) secukinumab and Vertex Pharmaceuticals Incorporated's (VRTX) ...
Sizzling news - Novartis AG (ADR) (NYSE:NVS), Royal Dutch Shell plc (NYSE ...
Manhattan, NY- September 30, 2014 - (Techsonian) - Novartis AG (ADR) (NYSE:NVS)offers patented prescription medicines in a variety of therapeutic areas, including oncology; most important care and established medicines; specialty care, such as ...
Related articles »  
Novartis AG (ADR)(NYSE:NVS) Drug Signifor LAR To Be Used For Treating ...
Boston, MA 09/29/2014 (wallstreetpr) - According to reports, Novartis AG (ADR)(NYSE:NVS)'s drug Signifor LAR has got the recommendation of CHMP for the approval of EU.
Related articles »